The aim of this study was to investigate a series of 3' and 5-substituted 2',3' -dideoxyuridine derivatives (ddUD) with respect to plasma protein binding, halflife and distribution across the blood-brain barrier in the rat. The microdialysis technique was used to study protein binding in human plasma (in vitro), and to sample the extracellular space of rats with microdialysis probes implanted into the striatum of the brain and the gastrocnemic muscle (in vivo). The compounds were analysed by HPLC with UV-detection. The octanol/water partition coefficients of the dduD varied from 0.08-0.84. The protein binding of the ddUDswas approximately 80%. After s.c. administration (25 or 50 mg kg-1 ), the brain and muscle extracellular levels differed; brain levels were 0.18-0.36 o] peripheral (muscle) concentrations. A multivariate analysis, which included data on zidovudine, alovudine and thymidine, demonstrated a relationship between the physicochemical and some of the phormacokinetic properties of uridine analogues. The analysis shows that half-life and protein binding increases with decreasing pK a . However, penetration to the brain is not correlated with the partition into octano!. It is concluded that the transport to the brain is not primarily dependent upon passive diffusion over a lipophilic barrier but, rather, to other chemical properties of the dduDs. This is suggestive of a specific transport mechanism, e.g. the thymidine carrier. 47 N Borg elal.
Introduction
Various strategies are used in the development of antiviral drugs in the form of structural analogues of nucleosides. In particular, modifications of3' substituent on the sugar moiety are used, due to the fact that this may cause a chain termination in the synthesis ofviral nucleic acids. Thymidine analogues have proved to be effective as antiretroviral agents, and the in vitro and in vivo antiviral effects of alovudine (3'-fluorothymidine) and zidovudine (:'r-azidothymidine) have been well documented by Mitsuya et al. (1985) ; Matthes et al. (1987 Matthes et al. ( , 1988 ); Good and de Miranda (1992) ; and Sandstrom and Oberg (1993) . Their pharmacokinetic properties have also been studied in detail (Balis et al., 1989; Boudinot et al., 1990; Good and de Miranda, 1992; Ljungdahl-Stahle et al., 1992; Sandstrom and Oberg, 1993; Stahle et al., 1993) . 5-Chloro-2',3'-dideoxy-3'-fluorouridine as a selective anti-human immunodeficiency virus (HIV) agent has been also studied by Balzarini et al. (1989) ; Matthes et al. (1989) ; and Daluge et al. (1994) .
The pharmacokinetic properties of antiviral drugs are important for their in vivo effects, and a property of special interest is the ability of a drug to reach high concentrations in the central nervous system. Studies of this kind are motivated, in case of viruses such as HSV and HI¥, by the seriousness of central nervous system infections (Wiley et al., 1986; Vazeux, 1991; Coburn et al., 1992; Macchi et al., 1992) . Microdialysis (Ungerstedt, 1984; Stahle, 1991 ) offers a method for continuous monitoring of the unbound drug concentrations in the extracellular space of several organs in the same experimental animal (Stahle, 1991; Stahle et al., 1990 Stahle et al., , 1991a . The method has been used to study both 
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Materials and Experimental Procedures
Male Sprague-Dawley rats (weight, 180-350 g) were used throughout (B&K Universal AB, Sweden). The rats had free access to tap water and standard lab chow and were housed 5-6 per cage. Each rat was used once only.
Micro dia lysis
The aim of the method is to sample endogenous and exogenous substances in their unbound form from the extracellular space. This is achieved by inserting a thin dialysis tube into a tissue and collecting dialysates, containing small molecules (molecular cut-off depends on the membrane but is typically 20 kDa) which diffuse from the extracellular fluid to the medium used to perfuse the dialysis probe. The method allows the collection of many samples without disturbing the blood and extracellular volume, and the samples are sufficiendy clean to allow direct analysis by reversed-phase high-pressure liquid chromatography (HPLC) without sample purification steps.
In the present study, rats were anaesthetized by halothane during the whole experiment and were placed in a David Kopf stereotaxis instrument with the bite bar 2.5 mm below the interaurealline. Dialysis probes (0.50 mm diameter, 4.0 mm long membrane) of the concentric type (CMA Microdialysis, Stockholm, Sweden) were implanted into the corpus striatum on one side of the brain (stereotaxic co-ordinates are: 2.2 mm lateral and 1.3 mm anterior to the bregma and 7.5 mm ventral to the brain surface) and into the gastrocnemius muscle. Each dialysis probe was perfused with Ringer's solution at a rate of 0.50~min-1 and samples of 15 JlL were collected at 30 min intervals. The in vivo recovery of each dialysis probe was determined in the following way.
After implantation and a 60 min washout period, the perfusion medium was switched from the Ringer solution to an aqueous solution containing 10 JlM (FMMdU, FCdU) or 50 J1M (FEdU) of the compound, which was injected systemically later. Two samples were collected and the perfusion medium was switched back to the Ringer solution. After a second washout period of 45-75 min, no drug was detectable in the dialysates. The proportion of drug lost over the dialysis membrane was taken as an estimate of the in vivo recovery over the dialysis membrane (Stahle, 1991) .
Mter the second washout period, FMMdU (25 mg kg-l, n = 4) or FEdU (50 mg kg-l, n = 3) or FCdU (50 mg kg-l, n = 4) was injected subcutaneously and six samples were collected postinjection during 180 min. The concentration measured in the dialysate was converted to estimates of the unbound extracellular concentration as R]
Thymidine Alovudine Zidovudine FCdu FEdU FMMdU 5-methoxymethyl-2' ,3' -dideoxy-3'-fluorouridine (FMMdU), 5-ethynyl-2',3'-dideoxy-3'-fluorouridine (FEdU) and 5-chloro-2 ',3'-dideoxy-3'-fluorouridine (FCdU) were synthesized according to known methods (Paquette and Farley, 1967; Bamford et al., 1990; ) at Medivir AB, Huddinge, Sweden. The preparation, injected s.c., was made by dissolving the compounds in a mixture of water (25%) and dimethylsulphoxide (75%) to a final concentration of 25 mg mL-1 (FMMdU) and 50 mg mL-1 (FEdU and FCdU).
thymidine analogues by Ljungdahl-Stahle et al. (1992) and Stahle et al. (1993) , and acyclic guanosine analogues by Stahle and Oberg (1992) .
The aim of the present study was to investigate a series of 5-substituted 3'-fluorouridine derivatives, with respect to plasma protein binding and distribution across the blood-brain barrier in the rat, in order to determine which chemical properties of the compounds influence these pharmacokinetic characteristics of the drugs. The chosen ddUD: 5-methoxymethyl-2',3'-dideoxy-3'-fluorouridine (FMMdU), 5-ethynyl-2',3'-dideoxy-3'-fluorouridine (FEdU); 5-chloro-2',3'-dideoxy-3'-fluorouridine (FCdU) offer 5-substituted modifications of 3'-fluorouridine with H 3C-O-CH2 -, HC::C-and CI-, respectively, in the 5 position of the uracil base. To extend the range of variation in chemical structures, the final analysis includes data previously published on AZT, FLT and thymidine (Stahle et al., 1993) . All chemical structures are given in Fig. 1 . described above. The mean recovenes were; muscle 0.236 and brain 0.088 for FMMdU; muscle 0.198 and brain 0.145 for FEdU; muscle 0.234 and brain 0.122 for FCdU
Plasma protein binding
Plasma protein binding ofFEdU, FMMdU, FCdU and thymidine was determined by micro dialysis as described by Herrera et al. (1990) and Stahle et al. (1990) . Each compound was added to human plasma to a total concentration of 40 (FEdU) or 100 (FMMdU and FCdU) flM. The recovery of each compound was determined for each dialysis probe using a stirred Ringer solution kept at 37°C containing a known concentration of the compound (C m ) into which the dialysis probe was inserted. Dialysis samples were collected and the concentration was measured (Cd)' The recovery is the ratio R = Cd fC m . The mean recoveries (R) were 0.71 (FMMdU, FEdU) and 0.75 (FCdU) in these experiments. The dialysis probe was then inserted into the 40 or 100 flM plasma solution of compounds which were stirred in the same way as the Ringer solution, and the dialysate concentration was measured. The free concentration was then calculated as the dialysate concentration divided by R. The ratio of free concentration to the total concentration is then the fraction unbound lfu) and 1-jit is the fraction bound to plasma protein.
Analysis of 3'-fluorouridine derivatives
The concentrations of FEdU, FMMdU and FCdU in dialysates were analysed by HPLC. The HPLC column used was a 100 X 2.1 mm 5 micron particles size C 18 column that was eluted by 10% methanol in 0.05 M (NH 4)H2P04 with pH 5.6. The ultraviolet (UV) absorbance at 254 nm was recorded, and the concentration determined by measuring the peak heights (Stahle et al., 1995) . The 3'-fluorouridine derivatives were easily separated from endogenous compounds both in the brain and in the muscle dialysates. The mean within-day coefficients of variation for peak-heights were 1.3%, 0.6% and 0.3% for FCdU, FEdU and FMMdU, respectively.
Partition coefficient octanol:water.
Equal volumes of octanol and a 100 flM aqueous solution of 3'-fluorouridine derivatives and thymidine were mixed by shaking with a vortex mixer and the phases were separated by centrifugation at 3500 r.p.m. for 2 min. The concentration of compounds in the aqueous phase was determined by HPLC before the mixing of phases and after centrifugation. The concentration of each compound in the octanol phase was calculated as the differ-Antiviral Chemistry & Chemotherapy 8( 1) 2',3' -dideoxyuridine derivatives: distribution to the brain and protein binding ence between the concentrations in the aqueous phase before the mixing of phases and after their separation.
Determination of pK a
The pK a was estimated by measuring the pH of watersolution of each 3'-fluorouridine derivatives to which NaOH was added such that, on a molar basis, the amount of NaOH was 50% the amount of the compound. That was described in detail for alovudine and zidovudine (Stahle et al., 1993) and two acyclic guanosine analogues (Stahle and Oberg, 1992) .
Experimental design and statistics
The design was a simple time-concentration curve. Because the samples were collected for 30 min, they are represented in the graphs as the mid-point of the collection period (i.e. 15, 45, 75'00 ..165 min) which is an acceptable approximation (Stahle, 1992 (Stahle, , 1993a . Data for each compound are plotted in time-vs.-log (concentration) diagrams. The half-life was calculated as In/slope where the slope of the elimination phase was determined by linear regression. The AUC (area under the time vs, concentration curve) was calculated by summing the products between the sampling interval (30 min) and the sample concentration (corrected for recovery) (Stahle, 1992 (Stahle, , 1993b .
A multivariate statistical analysis of the relation between physicochemical properties ofuridine analogues and their pharmacokinetic properties was made by means of partial least squares analysis (Stahle and Wold, 1986) . The compounds were physicochemically characterized by employing a substituent scale constructed for aromatic compounds by means of principal component analysis (Skagerberg et al., 1989) . Three scales were used for 3' and 5-substituent, where the first one is mainly related to sterical bulk and hydrophobicity since length, molecular refractivity and n, the second is dominated by the two electronic parameters, amand an'while the third is mainly hydrophobicity (n), In this analysis, data from previous studies of alovudine (n = 4), zidovudine (n = 4) and thymidine (n = 3) were included in order to cover a larger range of physico-chemical and pharmacokinetic properties.
Results
Protein binding
Plasma protein binding was found to be 86% (FMMdU), 83% (FEdU), 80% (FCdU). The binding of thymidine to plasma proteins was 22%. 
Muscle and brain distribution
The mean time-concentration curve for FMMdU, FEdU and FCdU are given in Figs 2, 3 and 4, respectively.The maximum concentration ofFMMdU in muscle (C = 34.3 "l\iT) as well as in the brain (C = 9.7 max J-LL1'~max ) was attained 45 min after the subcutaneous injection (25 mg kg-I) and the compound was then eliminated with a half-life of 42 min in muscle and 54 min in the brain. The AUCo-I80 ratio between brain and muscle was 0.23. 50 The maximum concentration, and therefore the time to maximum concentration in the dialysate for extracellular concentrations in the brain and muscle for FEdU (s.c. 50 mg kg-I), could not be estimated because of the persistent increase in concentration during collection of samples both in muscle and brain. The concentration of the compound at the last time-point in muscle and the brain was 59.4~and 13~, respectively. The AUCo-I80 ratio between brain and muscle was 0.18.
The maximum concentration of FCdU in muscle (42.5~) and in the brain (15.9~) was attained 75 FLT.
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Obs. K min (s.c. 50 mg kg-i) and FCdU was then eliminated with half-lives of 59 min and 87 min in the respective tissues. The ratio of the AUC between brain and muscle for FCdU was 0.36 which is greater than for the other 3'-fluorouridine derivatives.
Physicochemical properties of the FUDs
The partition coefficient octanol:water for 3'-fluorouridine derivatives was found to be 0.22 (FMMdU), 0.30 (FEdU) and 0.84 (FCdU) while the partition coefficient of thymidine was 0.06. The estimated pK a values were 8.5,7.5 and 7.4 for FMMdU, FEdU and FCdU, respectively.
Multivariate analysis of physicochemical properties vs. pharmacokinetics
In the partial least squares analysis pK a , partition coefficient octanollwater and molecular weight and substituent scales were used to predict AUC ratio brain to muscle, elimination rate constant (K) and plasma protein binding. Predicted AUC ratios and eliminate rate constants were compared with observed values (Figs 5, 6 ). This analysis included previously obtained data from thymidine, zidovudine and alovudine, together with the three compounds primarily studied in this paper. The analysis shows that elimination rate constant is quite strongly correlated to physico-chemicals properties of 5substituent uridine analogues and the half-life increases with decreasing pK a Binding to plasma proteins is more related to pK a than to partition coefficient octanollwater and for this parameter the properties of both the 3'-and Antiviral Chemistry & Chemotherapy 8( 1) 2',3'-dideoxyuridine derivatives: distribution to the brain and protein binding 5-substituents had an influence. Penetration to the brain (AUC ratio brain to muscle) was not related to the partition into the octanol phase, instead, the pK a and the properties of 5-substituent (increased size and reduced lipophilicity and electronic charge distribution) seemed, to determine this parameter. The number of compounds is too small to allow hypothesis testing and the analysis should be considered as descriptive.
Discussion
The pharmacokinetic properties and physico-chemical parameters of the presently studied FCdU, FMdU and FEdU have not been investigated previously, but properties of the structurally related thymidine analogues alovudine (3'-fluoro-thymidine) and zidovudine have been compared in rats (Stahle et al., 1993) and monkeys (Ljungdahl-Stahle et al., 1992) . In the present study, it was found that the binding of 5-substituted 3'-fluorouridine derivatives to plasma proteins is considerably higher than what was found for zidovudine and alovudine (Stahle et al., 1993) . The ratio of AUCo--18o brain:muscle for the 5-substituted 3'-fluorouridine derivatives was found to be between 0.18-0.36, while the same parameter for alovudine was 0.26 and for zidovudine 0.19 (Stahle et al., 1993) .
A common assumption is that the transport of drugs over the blood-brain barrier depends primarily on their lipophilicity. Hence, a small partition coefficient in octanol:water which indicates a low solubility in lipids is expected to correlate to a low rate of transport into the brain. Furthermore, a low concentration in the extracellular space of the brain would be expected from such a compound. The difference between octanol:water coefficients: 0.22, 0.30 and 0.84 is consistent with the difference between the AUC ratio for FMMdU (0.23), FEdU (0.18) and FCdU (0.36). However, the ratio of AUC for alovudine was 0.26 while its partition coefficient was 0.72 and zidovudine, with a partition coefficient of 1.44 has an AUC ratio of only 0.19. The multivariate analysis does not provide any evidence for a correlation between lipophilicity and brain levels of the compounds studied. We are thus forced to conclude that factors other than lipophilicity are the main determinants of the transport to the brain of these nucleoside analogues. One explanation which seems feasible is that the nucleosides are transported via particular carrier proteins and such carriers have been described by Cornford and Oldendorf (1975); and Spector and Berlinger, (1982) . For such transport systems it is the affinity to the transporter which determines the rate of transport to the brain. Our multivariate analysis suggests precisely this. The main factor influencing the AUC ratio was the descriptors of the 5-substituent which is what one would expect from an interaction between a transport protein and a small molecule.
Applications of micro dialysis to measure concentration differences over the blood-brain barrier of antiviral drugs can have some advantages when compared to methods like single-pass extraction after intracarotid injections or whole tissue measurements after systemic administration. Firstly, when the micro dialysis method is applied simultaneously to brain and muscle (or venous blood) there is no need for a separate measurement of unbound plasma concentration. Second, the collection of many samples by this method does not disturb the extracellular volume in brain and peripheral tissues (including plasma) and therefore the whole time-concentration curve can be followed in each single animal. This has the double advantage that interindividual variation is reduced and is partly replaced by intersample (intraindividual) variation and that a smaller number of experimental animals need to be used. Another advantage is that the samples are sufficiently clean to allow direct analysis by reversed-phase HPLC without purification steps. Therefore, the micro dialysis is a possible alternative to the methods used previously to measure nucleoside transport through the blood-brain barrier.
Blood concentrations of fluoro-uridine analogues were not determined in this study because the previous studies did not demonstrate significant differences between blood and muscle concentrations of other nucleoside analogues measured by micro dialysis in the rat (Stahle and Oberg, 1992; Stahle et al., 1993) and the monkeys (Ljungdahl-Stiihle et al., 1992) . In Fig. 7 the correlation is shown between blood and muscle concen- Muscle concentration (IlM) 52 trations of five different compounds measured in 16 different experiments at different time points after injection in rats (data from the previously published experiments). These data demonstrate clearly the equivalence between blood sampling and muscle sampling with microdialysis. In fact, it is our experience that variability is larger with blood sampling. Thus, the present study demonstrates that the physicochemical properties of uridine analogues correlate with pharmacokinetic properties such as protein binding and half-life. Penetration to the brain is not correlated with the partition into octanoL It is concluded that the transport to the brain is not primarily dependent upon passive diffusion over a lipophilic barrier but rather to other chemical properties of the ddUDs. This is suggestive of a specific transport mechanism, e.g. the thymidine carrier. 0/the National Academy 0/Sciences, USA 82:7096-7100. 
